# CellinCells

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellincells

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.cellincells.com
- Total disclosed funding: $14M
- Latest round: Series B (Jul 23, 2021)
- Investors on record: 7

## About

Based in Seoul, South Korea, and founded in 2014, CellinCells develops regenerative therapies by devising the self-structuring ability of cells as a platform technology. The company saw the potential for use of regenerative therapy while researching the self-structuring ability of cells. CellinCells focused on the development of skin regeneration treatments through 3D tissue shape platform technology. In 2016, the company obtained a patent for a structure for tissue regeneration and manufacturing method. In 2018, CellinCells signed a Research Consignment Contract with Seoul National University Industry-Academic Cooperation Foundation (Seoul National University Hospital Orthopedic Surgery).

The company is focused on research and development for its regenerative medicine stem cell therapy technology.

CellinCells plans to conduct clinical trials in cooperation with Samsung Seoul Hospital and others.

## Funding rounds

- Series B, Jul 23, 2021, $10M — Korea Investment Partners, L&S Venture Capital, Kolmar Korea, JX Partners, Ulmus Investment, Creation Investment Advisory
- Series A, Feb 1, 2019, $3.1M — KB Investment, JX Partners, Ulmus Investment, Creation Investment Advisory

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A
- JX Partners (https://capitalatlas.ai/funds/jx-partners) — Series A, Series B
- Ulmus Investment (https://capitalatlas.ai/funds/ulmus-investment) — Series A, Series B
- Creation Investment Advisory (https://capitalatlas.ai/funds/creation-investment-advisory) — Series A, Series B
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series B
- L&S Venture Capital (https://capitalatlas.ai/funds/l-s-venture-capital) — Series B
- Kolmar Korea — Series B